Professional Documents
Culture Documents
COMMENTARY
Address for correspondence: Dr Adam Jacobs, Dianthus Medical Limited, Lombard Business Park, 8
Lombard Road, London SW19 3TZ, UK. Tel: +44 20 8543 9229; Fax: +44 20 8543 9885;
email: ajacobs@dianthus.co.uk
Key words: Ghostwriting Ghost authorship Guidelines Medical writing Professional ethics
Publications
ABSTRACT
Background: Many papers in biomedical journals the draft from a range of interested parties.
are drafted not by the named authors, but by Findings and conclusions: The guidelines
professional medical writers working under stress the importance of respecting widely
the direction of those authors, usually funded recognised authorship criteria, and in particular
by pharmaceutical companies. Although this of ensuring that those listed as named authors
practice can improve both the quality and speed have full control of the content of papers. The
of publications, it has attracted controversy as role of medical writers must be transparent,
a result of concerns about the inappropriate which normally means a mention in the
influence of pharmaceutical companies. acknowledgements section, together with a
Objectives: To define ethical standards for statement about funding. Writers and authors
professional medical writers who prepare papers must have access to relevant data while writing
for publication in medical journals. papers. Medical writers have professional
Consensus methods: Guidelines were drafted responsibilities to ensure that the papers they
after a 4-round Delphi consultation among a group write are scientifically valid and are written in
of experienced medical writers. The guidelines accordance with generally accepted ethical
were then further refined by seeking comments on standards.
Background to the guidelines The issues about involving medical writers and the
appropriate role of sponsors are separate but sometimes
The need for guidelines
overlap. Although many guidelines already exist that
Medical journal editors have expressed concern about cover the preparation of manuscripts for peer-reviewed
the role of commercial sponsors in publishing research publications, none specifically provides guidance to
relating to their products and, in particular, about the medical writers who prepare publications on behalf
use of professional medical writers (who were not of named authors. The European Medical Writers
involved with the research) to develop publications. Association (EMWA) has developed this document to
318 EMWA guidelines 2005 LIBRAPHARM LTD Curr Med Res Opin 2005; 21(2)
articles, for example if they have conducted an extensive To qualify as authors, investigators (or others involved
literature search. It is important to note that by agreeing with a trial such as statisticians) need to have an
to be listed as an author, the medical writer takes public opportunity to make a substantial contribution to the
responsibility for the research. publication. This will usually involve commenting on
Although the Vancouver criteria have been widely an outline, or discussing key points before a first draft
adopted, some journals supplement the traditional is prepared, then having sufficient time to comment
author by-line with a contributor list indicating each on draft versions, and will always involve review and
individuals contribution to the research and the approval of the final version. Medical writers are often
publication. In such cases, it might be appropriate to list well placed to ensure that this process is properly
a medical writer who had prepared a first draft or made carried out, by advising on timetables for review and
some other significant contribution to the publication. ensuring that named authors have the materials required
Any specific requirements of the journal in this respect to perform a proper review (e.g. data tables and
should be followed. background literature).
2005 LIBRAPHARM LTD Curr Med Res Opin 2005; 21(2) EMWA guidelines Jacobs and Wager 319
It is not usually necessary or desirable for authors to sponsored by a company with a financial interest in
have access to individual patient data listings, as results their content, e.g. when a publication is sponsored by
become meaningful only after the raw data have been the company that markets a product described in it.
analysed, and tables and graphs produced. This analysis The writer and named authors should have access to
should usually be done by a statistician rather than by all relevant information and should ensure that all such
a clinician. However, there will be occasions where data, e.g. full safety data, are included in the publication
access to anonymised individual patient data is useful rather than selectively reported. The writer should also
(for example when reporting details of serious adverse ensure that conclusions are fully supported by the data
events), and in those cases medical writers should ensure and that publications do not contain unjustified claims.
that the data are made available both to themselves and Secondary publications and post-hoc analyses must be
to the named author(s). clearly identified as such. Medical writers should also
Both the medical writer and the named author(s) draw attention to any limitations of the study in the
must have access to the relevant study data, for example discussion section.
a clinical study report or set of statistical tables, before When preparing review articles (whether systematic
starting work on the publication. In addition, the writer or non-systematic), writers should ensure that the search
must have access to the study protocol in order to criteria are stated. Even in non-systematic reviews, all
identify secondary endpoints and analyses. Authors relevant major studies should be included and not only
should not be expected to comment on a publication if those that support the key message of the review.
they have not had access to the underlying data. If a writer is aware of good quality evidence that
contradicts a point being made in a review, or in the
Writers professional and ethical discussion section of a primary publication, the writer
responsibilities should attempt to ensure that this research is cited.
All medical writers, whether they are directly employed Implementation of these guidelines
by a sponsoring body, or work for an agency, or as a free-
lancer hired by the sponsor, should endeavour to ensure This document is intended to provide a framework for
that publications are produced in a responsible and professional medical writers in developing publications.
ethical manner and that relevant guidelines are met. We encourage companies who employ or hire medical
Medical writers should be aware of any guidelines writers to develop detailed procedures based on these
that apply to the publication they are producing (e.g. guidelines, for example giving standard wording to be
the ICMJE Uniform Requirements2, CONSORT for used in acknowledgements sections or contributor lists.
randomised trials4, GPP for industry-sponsored research3, EMWA affirms that professional medical writers
and individual journal and conference requirements). have a legitimate role in developing publications and
It is the writers responsibility to advise customers, their involvement should not be equated with sponsors
colleagues, and named authors if such guidelines are not attempting to exert undue influence over publications. In
being followed. fact, medical writers can raise the quality of publications
Medical writers should also advise customers and by bringing to the process language and communication
colleagues about the conventions of peer-reviewed skills, expertise in presenting data, understanding of
publications. For example, they should encourage clear publication guidelines and conventions, or time which
trial identification by including an ISRCTN5 (International investigators may lack. This position is set out in the
Standard Randomised Controlled Trial Number), accompanying position statement (see Appendix).
protocol or trial registry number, and discourage redun-
dant/duplicate and fragmented publications.
Medical writers must strive to ensure that the References
publications they develop are accurate and scientifically 1. Jacobs A. The involvement of professional medical writers in
valid. However, the named authors must take final medical publications: results of a Delphi study. Curr Med Res Opin
2005;21(2):3116
responsibility for the content of any publication
2. International Committee of Medical Journal Editors. Uniform
appearing under their names. requirements for manuscripts submitted to biomedical journals.
Writers must be aware of the extent of their expertise http://www.icmje.org [last accessed 13 January 2005]
3. Wager E, Field EA, Grossman L. Good publication practice for
on the subject on which they are writing, and should ask
pharmaceutical companies. Curr Med Res Opin 2003;19(3):149-
for guidance from the named author(s) for any parts of 54. Also available from http://www.gpp-guidelines.org [last
the paper that are beyond their own expertise. accessed 13 January 2005]
4. CONSORT statement. http://www.consort-statement.org [last
Writers and authors should ensure that results are
accessed 13 January 2005]
presented in a responsible and balanced fashion. This 5. ISRCTN. http://www.controlled-trials.com [last accessed 13
is particularly important when developing publications January 2005]
320 EMWA guidelines 2005 LIBRAPHARM LTD Curr Med Res Opin 2005; 21(2)
Background reading D Believes that properly trained medical writers
Angell M. The pharmaceutical industry to whom is it accountable? can make a positive contribution to manuscript
New Engl J Med 2000;342:1902-4 preparation. Such writers bring expertise about the
Anon. Ghost with a chance in publishing undergrowth. Lancet requirements of journals and congresses and the
1993;342:1498-9
Anon. The tightening grip of big pharma. Lancet 2001;357:1141 ethics and conventions of peer-reviewed biomedical
Bodenheimer T. Uneasy alliance. Clinical investigators and the publications. They also offer skills in language,
pharmaceutical industry. New Engl J Med 2000;342:1539-44
Davidoff F, DeAngelis CD, Drazen JM, et al. Sponsorship, authorship,
scientific communication, and data presentation.
and accountability. Ann Intern Med 2001;135:463-6 [also Lancet Such skills and knowledge enable professional writers
358:854-6] to prepare drafts that are clearly written and follow
Horton R. Signing up for authorship. Lancet 1996;347:780
Horton R. The unmasked carnival of science. Lancet 1998;351:688-9 the relevant guidelines. Involving medical writers
Huston P, Moher D. Redundancy, disaggregation, and the integrity of may therefore raise the standard of publications and
medical research. Lancet 1996;347:1024-6 accelerate the writing and publication process.
Lagnado M. Haunted papers. Lancet 2002;359:902
Rennie D. Conflicts of interest in the publication of science. J Am E Encourages medical writers to ensure that publications
Med Assoc 1991;266:266-7 are developed in a responsible and ethical manner,
Rennie D, Flanagin A. Authorship! Authorship! Guests, ghosts, grafters
as specified in the guidelines that accompany this
and the two-sided coin. J Am Med Assoc 1994;271:469-71
Rennie D. When authorship fails. A proposal to make contributors position statement; in practice this means:
accountable. J Am Med Assoc 1997;278:579-85
Rennie D. Thyroid storm. J Am Med Assoc 1997;277:1238-43 keeping up-to-date with relevant guidelines
Rennie D, Flanagin A, Yank V. The contributions of authors. J Am
Med Assoc 2000;284:89-91 (e.g. CONSORT, ICMJE, GPP) and journal or
Sharp D. A ghostly crew. Lancet 1998;351:1076 conference requirements for financial disclosures
Smith R. Maintaining the integrity of the scientific record. Br Med J or statements about competing interests
2001;323:588
advising colleagues and customers about these
guidelines and/or conventions on responsible
publication or authorship and alerting them if
Appendix: EMWA position they are not being followed
statement on the role of involving the named author(s) early in the
medical writers in developing publication process
peer-reviewed publications refusing requests to develop publications without
sufficient involvement of the named author(s)
making their best efforts to ensure that publications
The European Medical Writers Association (EMWA):
are accurate, balanced, and scientifically valid,
acknowledging the limitations of their expertise
A Affirms that medical writers have a legitimate role in and seeking guidance where needed
assisting named authors in developing manuscripts for taking particular care to present results relating
peer-reviewed journals and material for presentation to the sponsors product in a fair and balanced
at peer-reviewed scientific meetings. fashion
B Believes that such contributions and relevant endeavouring to ensure that the named author(s)
information about funding should be openly has access to the necessary data and adequate
acknowledged. time to contribute to a publication
C Discourages use of the term ghostwriter to describe endeavouring to ensure that all named authors
professional medical writers, as this term implies that approve the final version before submission to a
there is something secretive about the involvement journal or conference
of the writer. Rather, the involvement of professional refusing requests to develop publications in an
medical writers should always be transparent. unethical or irresponsible manner.
CrossRef links are available in the online published version of this paper:
http://www.cmrojournal.com
Paper CMRO-2887B_5, Accepted for publication: 21 January 2005
Published Online: 24 February 2005
doi:10.1185/030079905X25578
2005 LIBRAPHARM LTD Curr Med Res Opin 2005; 21(2) EMWA guidelines Jacobs and Wager 321